Effect Inhaled Nitric Oxide in Adult Liver Transplant

NCT ID: NCT07125443

Last Updated: 2025-08-15

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 260 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-01
• Study Completion Date: 2027-01-01

Brief Summary

Liver transplantation remains the only cure for patients with end-stage liver disease. Despite continuous advances in medical care, ischemia-reperfusion injury (IRI) (tissue damage that occurs when blood supply is restored to an area that has been deprived of oxygen) remains a major contributor to complications with the newly transplanted liver. IRI can lead to a condition known as post-reperfusion syndrome that involves profound narrowing of blood vessels, significantly low blood pressure, and an increased requirement of medication to control blood pressure. In some cases, post-reperfusion syndrome can progress to a condition known as post-reperfusion vasoplegia which is a condition where severely low blood pressure persists even after blood flow is restored to the liver. This is often accompanied by complications such as improperly functioning kidneys, blood clotting disorders, and complications with the transplanted liver that can significantly affect patient outcomes. Recent studies have shown than inhaled nitric oxide (a gas that can relax blood vessels) can reduce the severity of IRI in the liver. This study is being conducted to determine whether the administration of inhaled nitric oxide during surgery reduces the severity of post-reperfusion syndrome and the incidence of post-reperfusion vasoplegia in adult patients undergoing liver transplantation. This is a before-and-after study design that will involve both the retrospective collection of data between the time period of January 1, 2020 - May 31, 2025 and prospective interventions involving adult liver transplant recipients.

Detailed Description

Orthotopic liver transplantation remains the only curative option for patients with end-stage liver disease. Despite continuous advances in surgical techniques and perioperative management, ischemia-reperfusion injury (IRI) remains a major contributor to early graft dysfunction, with clinical consequences including prolonged intensive care stay, increased morbidity, and higher resource utilization. Reperfusion of the donor liver, particularly after portal and arterial unclamping, frequently triggers a hemodynamic instability known as post-reperfusion syndrome. This syndrome is characterized by profound vasodilation, hypotension, and a significant increase in vasopressor requirements. In some patients, it progresses into post-reperfusion vasoplegia, a state of sustained low systemic vascular resistance and poor end-organ perfusion. This condition is often accompanied by renal dysfunction, coagulopathy, and impaired early graft function, which significantly affect patient outcomes.

The pathophysiology of hepatic IRI is complex, involving endothelial activation, neutrophil recruitment, oxidative stress, mitochondrial dysfunction, and cytokine release. A key mechanistic factor contributing to reperfusion injury is the reduced bioavailability of nitric oxide (NO), due either to decreased production by endothelial nitric oxide synthase (eNOS) or its rapid inactivation by reactive oxygen species and heme-containing proteins. NO plays an essential role in maintaining microvascular tone, limiting leukocyte adhesion, and protecting against mitochondrial and endothelial injury. Restoration of NO signaling has been shown to protect against IRI in preclinical models. Inhaled nitric oxide (iNO) is approved for pulmonary hypertension and neonatal hypoxemia, but accumulating evidence suggests that it may also exert extrapulmonary effects. Studies in both animals and humans have demonstrated that iNO can attenuate IRI in the liver, heart, and skeletal muscle by increasing circulating nitrite and other bioactive NO metabolites that act as reservoirs and mediators of NO activity during ischemic stress.

In the context of liver transplantation, two retrospective clinical studies have shown that intraoperative iNO administration (at 80 ppm (parts per million)) is safe and may accelerate the recovery of liver function, reduce hepatocellular apoptosis, and decrease postoperative complications. These findings suggest that iNO could modulate the hemodynamic response to reperfusion and improve graft performance. However, despite these promising results, no prospective controlled trials or before-after studies have yet evaluated the real-time impact of intraoperative iNO on reperfusion syndrome and vasoplegia in liver transplantation.

The investigators hypothesize that the intraoperative administration of inhaled nitric oxide reduces the severity of reperfusion syndrome and the incidence of post-reperfusion vasoplegia in adult patients undergoing liver transplantation. Furthermore, the investigators propose that this intervention contributes to improved early graft function, particularly with regard to excretory performance. The present study aims to prospectively assess these outcomes using a before-after design, comparing matched cohorts of patients undergoing liver transplantation with and without intraoperative iNO. By addressing this existing gap in the literature, the investigators hope to generate clinically relevant data that may support the integration of iNO into standard perioperative protocols for liver transplant recipients.

This study involves 2 patient groups:

1. Retrospective "before" group (control arm): Adult liver transplant recipients identified retrospectively from the institutional transplant database, including all patients who underwent orthotopic liver transplantation since the implementation of the OneChart electronic medical record (EMR) system at London Health Sciences Centre between the time period of January 1, 2020 - May 31, 2025.

2. Prospective "after" group (intervention arm): 60 consecutive adult patients undergoing liver transplantation after the implementation of the iNO protocol, with prospective intervention involving intraoperative administration of iNO and prospective data collection.

For the prospective, "after" study group, the participant's liver transplant procedure will proceed according to plan. Informed, written consent will be obtained prior to the start of surgery.

Inhaled nitric oxide will be administered via the anesthesia machine, under the supervision of the attending Anesthesiologist, at a concentration of 20 parts per million (ppm) starting at induction of anesthesia. At the onset of the anhepatic phase (i.e., after explantation of the native liver), the concentration will be increased to 80 ppm. Administration will be continued until the end of the surgical procedure, at which point iNO will be discontinued. Standard anesthesia and transplant protocols will be followed in both groups, with no additional changes aside from the administration of iNO.

Participation in the "before" group will only involve retrospective data collection from the patients' electronic medical record that will gather data collected during the period of January 1, 2020 - May 31, 2025.

Data that will be collected include demographic data, medical history, intraoperative surgical details, details of iNO administration (where applicable), and post-operative outcomes. The timeline for collecting postoperative outcomes will be between 0-72 hours following surgery.

Conditions

Liver Diseases; Reperfusion Injury; Vasoplegia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

No Intervention Retrospective "Before" Group

Adult liver transplant recipients identified retrospectively from the institutional transplant database, including all patients who underwent orthotopic liver transplantation since the implementation of the OneChart electronic medical record (EMR) system between the time period of January 1, 2020 - May 31, 2025.

Group Type: ACTIVE_COMPARATOR

No Intervention Retrospective "Before" Group

Intervention Type: OTHER

Adult liver transplant recipients identified retrospectively from the institutional transplant database, including all patients who underwent orthotopic liver transplantation since the implementation of the OneChart electronic medical record (EMR) system between the time period of January 1, 2020 - May 31, 2025.

Prospective iNO Administration ("After" Group)

Adult patients undergoing liver transplantation with prospective intervention involving intraoperative administration of inhaled nitric oxide (iNO) and prospective data collection.

Group Type: EXPERIMENTAL

Prospective iNO Administration ("After" Group)

Intervention Type: DRUG

Adult patients undergoing liver transplantation after the implementation of the iNO protocol, with prospective intervention involving intraoperative administration of iNO and prospective data collection. Inhaled nitric oxide will be administered via the anesthesia machine, under the supervision of the attending Anesthesiologist, at a concentration of 20 parts per million (ppm) starting at induction of anesthesia. At the onset of the anhepatic phase (i.e., after explantation of the native liver), the concentration will be increased to 80 ppm. Administration will be continued until the end of the surgical procedure, at which point iNO will be discontinued.

Interventions

Prospective iNO Administration ("After" Group)

Adult patients undergoing liver transplantation after the implementation of the iNO protocol, with prospective intervention involving intraoperative administration of iNO and prospective data collection. Inhaled nitric oxide will be administered via the anesthesia machine, under the supervision of the attending Anesthesiologist, at a concentration of 20 parts per million (ppm) starting at induction of anesthesia. At the onset of the anhepatic phase (i.e., after explantation of the native liver), the concentration will be increased to 80 ppm. Administration will be continued until the end of the surgical procedure, at which point iNO will be discontinued.

Intervention Type: DRUG

No Intervention Retrospective "Before" Group

Adult liver transplant recipients identified retrospectively from the institutional transplant database, including all patients who underwent orthotopic liver transplantation since the implementation of the OneChart electronic medical record (EMR) system between the time period of January 1, 2020 - May 31, 2025.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Adult patients (age ≥ 18 years)
• Undergoing or underwent (for the retrospective "before" group) primary orthotopic liver transplantation. Retrospective data collection for retrospective group will take place between January 1, 2020 - May 31, 2025.
• Written informed consent obtained for patients in the prospective ("after") group

Exclusion Criteria

• History of pulmonary arterial hypertension (mean pulmonary artery pressure ≥ 25 mmHg)
• Re-transplantation
• Acute fulminant hepatitis
• Combined organ transplantation (e.g., liver-kidney)
• Lack of complete data for propensity matching - Inability to communicate in the English language

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

Sponsor Role: lead

Responsible Party

Raffael Zamper

Anesthesiologist, Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Raffael Zamper

Role: PRINCIPAL_INVESTIGATOR

London Health Sciences Centre

Central Contacts

Raffael Zamper

Role: CONTACT

Raffael.PereiraCezarZamper@lhsc.on.ca

5196858500 ext. 13984

References

Lang JD Jr, Smith AB, Brandon A, Bradley KM, Liu Y, Li W, Crowe DR, Jhala NC, Cross RC, Frenette L, Martay K, Vater YL, Vitin AA, Dembo GA, Dubay DA, Bynon JS, Szychowski JM, Reyes JD, Halldorson JB, Rayhill SC, Dick AA, Bakthavatsalam R, Brandenberger J, Broeckel-Elrod JA, Sissons-Ross L, Jordan T, Chen LY, Siriussawakul A, Eckhoff DE, Patel RP. A randomized clinical trial testing the anti-inflammatory effects of preemptive inhaled nitric oxide in human liver transplantation. PLoS One. 2014 Feb 12;9(2):e86053. doi: 10.1371/journal.pone.0086053. eCollection 2014.

Reference Type: BACKGROUND

PMID: 24533048 (View on PubMed)

Lang JD Jr, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK, Liu Y, Jhala N, Crowe DR, Smith AB, Cross RC, Frenette L, Kelley EE, Wilhite DW, Hall CR, Page GP, Fallon MB, Bynon JS, Eckhoff DE, Patel RP. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest. 2007 Sep;117(9):2583-91. doi: 10.1172/JCI31892.

Reference Type: BACKGROUND

PMID: 17717604 (View on PubMed)

Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury. J Gastroenterol Hepatol. 2000 Jul;15(7):718-24. doi: 10.1046/j.1440-1746.2000.02207.x.

Reference Type: BACKGROUND

PMID: 10937675 (View on PubMed)

Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4651-5. doi: 10.1073/pnas.88.11.4651.

Reference Type: BACKGROUND

PMID: 1675786 (View on PubMed)

Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005 Feb;115(2):209-18. doi: 10.1172/JCI24282.

Reference Type: BACKGROUND

PMID: 15690074 (View on PubMed)

Duranski MR, Greer JJ, Dejam A, Jaganmohan S, Hogg N, Langston W, Patel RP, Yet SF, Wang X, Kevil CG, Gladwin MT, Lefer DJ. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest. 2005 May;115(5):1232-40. doi: 10.1172/JCI22493. Epub 2005 Apr 14.

Reference Type: BACKGROUND

PMID: 15841216 (View on PubMed)

Cannon RO 3rd. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem. 1998 Aug;44(8 Pt 2):1809-19.

Reference Type: BACKGROUND

PMID: 9702990 (View on PubMed)

Other Identifiers

iNO for LT

Identifier Type: -

Identifier Source: org_study_id